FungiScope - A Global Emerging Fungal Infection Registry

Invasive Fungal Disease Clinical Trial

— FungiScope  

Official title:

FungiScope - A Global Emerging Fungal Infection Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01731353
• Other study ID #: Fungi001
• Status: Recruiting
• Start date: March 2003
• Est. completion date: December 2026

Study information

• Verified date: December 2023
• Source: University of Cologne
• Contact: Oliver A Cornely, Prof.
• Phone: +49 221 478
• Email: oliver.cornely[@]uk-koeln.de
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of this registry is to broaden the knowledge on epidemiology, diagnostic procedures and clinical course of emerging invasive fungal infections.

Description:

The specific objectives are:

1. To determine the fungal species causing invasive fungal infection in different parts of the world.

2. To determine the clinical pattern of disease and document procedures performed for confirmation of the diagnosis.

3. To describe the therapeutic regimens used and their efficacy.

4. To share clinical isolates among the contributors of Fungiscope.

5. To develop molecular biology tools for identification of strains in histopathologically proven invasive fungal infection.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 2026
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Cultural, histopathological, antigen or DNA evidence of invasive fungal infection

Exclusion Criteria:

• Infection due to Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci

• Endemic fungal infection such as coccidioidomycosis or histoplasmosis

• Colonisation or other non-invasive infection

Related Conditions & MeSH terms

• Infections
• Invasive Fungal Disease
• Invasive Fungal Infections
• Mycoses

Locations

Country	Name	City	State
Germany	University Hospital Cologne	Cologne	NRW

Sponsors (6)

Lead Sponsor	Collaborator
University of Cologne	Basilea Pharmaceutica, Cidara Therapeutics Inc., F2G Biotech GmbH, Matinas Biopharma, Inc, Pfizer

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment efficacy of emerging fungal infections	failure, stable disease, partial response or complete response	At 90 days from diagnosis

External Links

•   FungiQuest - Search Engine for rare fungal infection
•   FungiScope - A Global Emerging Fungal Infection Registry